Papers/PMID:32829928
Zinc in depression: From development to treatment: A comparative/ dose response meta-analysis of observational studies and randomized controlled trials.
General hospital psychiatry2022The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
Zn(2+) — decreases depressive symptom severity (across unharmonised instruments)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“The meta-analysis of RCTs indicated that zinc supplementation significantly lowered depressive symptom scores of depressed patients [weighted mean difference (WMD = -4.15 point; 95% CI: -6.56, -1.75 point; P < 0.01)], and the improvement in depression status occurred only when zinc supplementation was prescribed as a monotherapy.”
Quoted verbatim from Zinc in depression: From development to treatment: A comparative/ dose response meta-analysis of observational studies and randomized controlled trials.. - Study
- meta-analysis
- Population
- Patients with depression; pooled RCTs, improvement reported only in trials giving zinc as monotherapy
Effect -4.15 mean difference, 95% CI -6.56 to -1.75
Zinc in depression: From development to treatment: A comparative/ dose response meta-analysis of observational studies and randomized controlled trials.2022PMID:32829928Permalink